Program areas at PVS
In 2020, pvs continued our fight against diarrheal diseases, the second-leading cause of death among children in low-income countries. To combat rotavirus, a major cause of severe diarrhea, we continued clinical development of a nonreplicating rotavirus Vaccine candidate. The phase 3 efficacy study that began in late 2019 was paused throughout 2020 due to the covid-19 pandemic in order to best protect the health and safety of participating infants and their families. Preparatory activities continued at the three clinical sites in africa throughout the year to ensure readiness to restart the trial once conditions allow. (continued on schedule o).this Vaccine candidate is administered as an intramuscular injection and could potentially overcome the lower efficacy levels seen in low-resource settings for oral, live attenuated rotavirus vaccines. In addition, pvs continued conducting a case-control study in india to evaluate the effectiveness of serum institute of india pvt. Ltd.'s (siipl's) licensed rotavirus Vaccine, rotasiil. The study was paused from late march 2020 to late november 2020 due to the covid-19 pandemic.pvs continued to support clinical trials and research on Vaccine candidates that may provide protection against enterotoxigenic escherichia coli (etec) and shigella, the leading bacterial causes of diarrheal illness. Currently, there are no licensed vaccines against either pathogen. In 2020, our work included completing the submission of results from a phase 1 trial of an injectable, subunit etec Vaccine candidate to the us food and drug administration. Pvs also partially supported the final data analysis for a phase 2b efficacy study of an oral etec Vaccine candidate in finnish travelers to benin, reporting results in march 2020.achieving world health organization prequalification in 2019 for pneumosil (a low-cost pneumococcal conjugate Vaccine [pcv] developed by pvs and siipl) triggered a unicef and siipl supply agreement in 2020, which at $2.00 per dose was more than 30 percent less expensive than other pcvs, improving affordability for low- and middle-income countries. In addition, pneumosil received market authorization in india, and a phase 3 clinical trial of pneumosil in the gambia also progressed.pvs added to the respiratory syncytial virus (rsv) maternal immunization knowledge base in 2020. We published several articles about the economic impact in low-income countries of rsv and other acute respiratory infections among infants, as well as a modeling exercise on the impact of a hypothetical maternal rsv Vaccine in protecting infants in countries supported by gavi, the Vaccine alliance.pvs also contributed an article on antenatal care timing, which could inform maternal Vaccine coverage, and a state-of-the-art review on the maternal immunization landscape. Additionally, we updated our rsv Vaccine and monoclonal antibody snapshot (which provides an overview of the intervention product landscape) and trial tracker (which provides information on related clinical trials).
Personnel at PVS
Name | Title | Compensation | Date of data |
---|
Brian Neville | Vice President Accounting and Financial Operations / Secretary and Treasurer | $0 | 2021-02-26 |
Olivia D Polius | Treasurer | $0 | 2019-12-31 |
Edward M Yoshida | Secretary | $0 | 2019-12-31 |
Stephen B Davis | Chair and President | $0 | 2019-12-31 |
David C Kaslow | Vice Chair | $0 | 2019-12-31 |
...and 4 more key personnel |
Financials for PVS
Revenues | FYE 12/2019 | FYE 12/2018 | % Change |
---|
Total grants, contributions, etc. | $9,933,910 | $34,948,159 | -71.6% |
Program services | $0 | $0 | - |
Investment income and dividends | $975,772 | $793,638 | 22.9% |
Tax-exempt bond proceeds | $0 | $0 | - |
Royalty revenue | $0 | $0 | - |
Net rental income | $0 | $0 | - |
Net gain from sale of non-inventory assets | $187,466 | $50,852 | 268.7% |
Net income from fundraising events | $0 | $0 | - |
Net income from gaming activities | $0 | $0 | - |
Net income from sales of inventory | $0 | $0 | - |
Miscellaneous revenues | $31,871 | $14,669 | 117.3% |
Total revenues | $10,961,263 | $35,807,318 | -69.4% |
Organizations like PVS
Organization | Type | Location | Revenue |
---|
INDEPTH Network | 501(c)(3) | Canada, | $3,589,660 |
Panorama Global | 501(c)(3) | Seattle, WA | $43,110,179 |
Global Alzheimer's Platform Foundation | 501(c)(3) | Washington, DC | $7,275,893 |
World Lung Foundation (WLF) | 501(c)(3) | New York, NY | $3,764,917 |
MiracleFeet | 501(c)(3) | Chapel Hill, NC | $4,071,692 |
African Economic Research Consortium (AERC) | 501(c)(3) | Kenya, | $9,007,243 |
Behring Global Educational Foundation (BGEF) | 501(c)(3) | Danville, CA | $27,708,835 |
Hearts In Motion | 501(c)(3) | Schererville, IN | $3,560,801 |
Equalize Health Formerly D-REV | 501(c)(3) | San Francisco, CA | $4,829,081 |
Intasave Caribsave Group | 501(c)(3) | United Kingdom, | $5,328,228 |
Data update history
August 23, 2021
Posted financials
Added Form 990 for fiscal year 2019
April 28, 2021
Posted financials
Added Form 990 for fiscal year 2018
April 8, 2021
Updated personnel
Identified 4 new personnel
December 18, 2018
Posted financials
Added Form 990 for fiscal year 2017
Nonprofit Types
Social advocacy organizationsInternational-focused organizations
Issues
Social sciencesHealthForeign affairsInternational developmentPublic policy
Characteristics
Provides grantsConducts researchOperates internationallyNo full-time employeesTerminated
General information
- Address
- 2201 Westlake Ave No 200
- Seattle, WA 98121
- Metro area
- Seattle-Tacoma-Bellevue, WA
- Website URL
- path.org/Â
- Phone
- (206) 285-3500
- Facebook page
- PATHglobalhealthÂ
IRS details
- EIN
- 83-0431851
- Fiscal year end
- December
- Taxreturn type
- Form 990
- Year formed
- 2006
- Eligible to receive tax-deductible contributions (Pub 78)
- No
Categorization
- NTEE code, primary
- Q33: International Relief
- NAICS code, primary
- 813319: Social Advocacy Organizations
- Parent/child status
- Independent
Free account sign-up
Want updates when PVS has new information, or want to find more organizations like Path Vaccine Solutions (PVS)?
Create free Cause IQ account